秋水仙碱预防肺切除手术患者围术期心房颤动的初步随机对照研究
在加拿大2个中心纳入100例≥55岁接受肺切除手术患者,随机接受秋水仙碱0.6 mg或安慰剂,术前数小时开始、术后每日两次再用9天;12个月完成招募,30天随访完整,秋水仙碱组新发术后房颤或房扑5例(10.2%)vs 安慰剂组7例(13.7%),校正风险比0.69(95%CI 0.20-2.34)。
要点
- 100例患者随机分组(秋水仙碱49例、安慰剂51例),12个月内在加拿大2个中心完成招募。
- 秋水仙碱组新发术后房颤或房扑5例(10.2%),安慰剂组7例(13.7%),校正风险比0.69(95%CI 0.20-2.34)。
- 71%患者无中断完成研究药物疗程,患者拒绝继续服药是永久停药的主要原因。
核心结论
- 结果表明在肺切除手术患者中评估秋水仙碱预防围术期心房颤动的试验是可行的,该初步研究将作为大型多中心COP-AF试验的基础。
研究设计与样本
- 初步随机对照研究,纳入≥55岁接受肺切除手术患者,随机接受秋水仙碱0.6 mg或安慰剂,术前数小时开始,术后每日两次再用9天。
- 共100例患者随机分组(秋水仙碱49例、安慰剂51例),在加拿大2个中心用12个月完成招募。
- 可行性结局包括招募100例所需时间、随访完整性和研究药物依从性;主要疗效结局为随机化后30天内的术后房颤或房扑。
主要发现
- 所有患者完成30天随访,招募和随访每例患者所需平均工作人员时间为165分钟。
- 71%患者无中断完成研究药物疗程,患者拒绝继续服药是永久停药的主要原因。
- 秋水仙碱组新发术后房颤或房扑5例(10.2%),安慰剂组7例(13.7%),校正风险比0.69(95%CI 0.20-2.34)。
关键数值与推荐
- 秋水仙碱组新发术后房颤或房扑5例(10.2%)vs 安慰剂组7例(13.7%),校正风险比0.69(95%CI 0.20-2.34)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: We carried out a pilot randomized controlled study to determine the feasibility of a large trial evaluating the impact of colchicine versus placebo on postoperative atrial fibrillation or atrial flutter (POAF) among patients undergoing lung resection surgery. METHODS: Patients ≥55 years of age undergoing lung resection surgery were randomly assigned to receive colchicine 0.6 mg or placebo starting a few hours before surgery. Postoperatively, patients received colchicine 0.6 mg or placebo twice daily for an additional 9 days. Our feasibility outcomes included the period of time required to recruit 100 patients, the completeness of follow-up and compliance with the study drug. The primary efficacy outcome was POAF within 30 days of randomization. RESULTS: One hundred patients were randomized (49 to colchicine and 51 to placebo) over a period of 12 months at 2 centres in Canada. All patients completed the 30-day follow-up. The mean staff time required to recruit and to follow-up each patient was 165 min. In all, 71% of patients completed the study drug course without interruption. Patient refusal to continuing taking the study drug was the main reason for permanent drug discontinuation. New POAF occurred in 5 (10.2%) patients in the colchicine group and 7 (13.7%) patients in the placebo group (adjusted hazard ratio 0.69, 95% confidence interval 0.20-2.34). CONCLUSIONS: These results show the feasibility of a trial evaluating Colchicine for the prevention of perioperative Atrial Fibrillation in patients undergoing lung resection surgery. This pilot study will serve as the foundation for the large multicentre COP-AF trial.
引用
- Bessissow A, Agzarian J, Shargall Y, et al. Colchicine for Prevention of Perioperative Atrial Fibrillation in patients undergoing lung resection surgery: a pilot randomized controlled study. Eur J Cardiothorac Surg. 2018. PMID: 29237033. doi:10.1093/ejcts/ezx422
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。